Eilean Therapeutics LLC has received approval from the Human Research Ethics Committee in Australia to commence a Phase I clinical trial for lomonitinib (ZE46-0134).

A recent Phase 1b clinical trial of topical pravibismane for managing moderate to severe diabetic foot ulcers has shown promising results.

TPST-1120, a novel oral PPAR⍺ inhibitor, has shown promising results in treating cancers that are resistant to PD-1 inhibitors and those with weakened immune systems.

LOTIS-7 Phase 1b Trial Completes Dose Escalation: ZYNLONTA® and Bispecific Antibodies for Non-Hodgkin Lymphoma Patients, No Severe Side Effects Observed.

Ocugen, Inc. has received approval from the Data and Safety Monitoring Board (DSMB) to advance to the medium dose cohort in the Phase 1/2 clinical trial for OCU410.

Geneos Therapeutics has reported successful results from its GT-30 clinical trial, showcasing the safety and effectiveness of a personalized therapeutic cancer vaccine (PTCV) for patients with advanced hepatocellular carcinoma (HCC).

The study, which focuses on the use of RP1 monotherapy for skin cancer treatment in transplant patients, was detailed at the AACR 2024 Annual Meeting.

The three-year outcomes from a Phase 1 study of a personalized mRNA cancer vaccine, autogene cevumeran (BNT122, RO7198457), have demonstrated sustained polyspecific T cell reactions and a reduction in tumor recurrence in patients.

Regeneron Pharmaceuticals has reported encouraging results from their Phase 1/2 clinical trial of linvoseltamab.

Vincerx Pharma, a biopharmaceutical firm, has reported encouraging preliminary results from the Phase 1 clinical trial of its drug candidate VIP236, which targets metastatic solid tumors.

May 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Clover Biopharmaceuticals, a leading biotech firm, has reported promising initial results from its Phase I clinical trial for SCB-1019, a novel bivalent RSV vaccine.